Pyc Therapeutics Limited (ASX:PYC)


right-arrow Created with Sketch. 0.01 (8.33%)
MCAP $413.5M
Last trade 16.10pm 28/01/2022 20mins delayed

Latest Announcements

27/01/2022 Price SensitivePSPYCPyc Therapeutics Limited
07/01/2022PYCPyc Therapeutics Limited
29/12/2021PYCPyc Therapeutics Limited
20/12/2021PYCPyc Therapeutics Limited
09/12/2021PYCPyc Therapeutics Limited
30/11/2021PYCPyc Therapeutics Limited
30/11/2021PYCPyc Therapeutics Limited
30/11/2021PYCPyc Therapeutics Limited

Company Overview

PYC Therapeutics Limited is an Australia-based drug-development company, which offers ribonucleic acid (RNA) therapeutics to meet unmet needs in disease. The Company has RNA targeted therapeutics design capabilities to deliver technology based on cell penetrating peptides (CPPs). The Company develops a pipeline of therapies, including three preclinical stage programs, which are focused on inherited eye diseases and preclinical discovery efforts, which are focused on neurodegenerative diseases. The Company’s lead drug candidate, VP-001 is designed to treat Retinitis pigmentosa 11 (RP11). The second lead drug candidate VP-002, which is focused on treating autosomal dominant optic atrophy (ADOA) and PYC-001 drug candidate to treat diabetic retinopathy. Its preclinical, clinical, regulatory and corporate operations are based in San Diego, California. The Company's discovery and laboratory operations are located in Australia.

PYC in the news

PYC Therapeutics (PYC) is set to progress to the first in-human trials…
PYC Therapeutics (PYC) confirms its drug delivery technology can reach the retina…
PYC Therapeutics (PYC) has made a significant breakthrough in the treatment of…
Drugmaker PYC Therapeutics (PYC) has successfully tapped institutions for $35.2 million in…

Search Previous Announcements